Mesoblast Ltd. | |
Stock Exchange | Australian Stock Exchange |
EPS |
AUD0.25 |
Market Cap |
AUD715.46 M |
Shares Outstanding |
498.63 M |
Public Float |
371.7 M |
Mesoblast Ltd. ADR | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.92 |
Market Cap |
$527.8 M |
Shares Outstanding |
99.73 M |
Public Float |
- |
Address |
55 Collins Street Melbourne Victoria (VIC) 3000 Australia |
Employees | - |
Website | http://www.mesoblast.com |
Updated | 07/08/2019 |
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia. |